"We still believe that 1999 will be Ligand's break-out year, and would use any weakness in the stock as a buying opportunity."
---------------------
Henry, I guesstimate that in early or mid 2000 Ligand could break into a new, more stable and secure phase of its life cycle, because of Targretin's success (good chance, and hopefully) against advanced HUMAN breast cancer.
(The triglyceride issue, IMO, will nix Targretin's use for long-term indications such as breast cancer "prevention," or long-term (5-year) adjuvant therapy after lumpectomy / mastectomy.)
I plan to buy again on weakness, but not on ANY weakness.
I have no plans to buy a falling knife today or tomorrow.
I'm waiting for the 4Q and annual report to come out. That's when I expect a bargain.
Last year, the 4Q press release came out on March 31st,
the same day the annual SEC report was filed.
Best wishes for the long haul,
Cheryl |
